Tech Company Financing Transactions
NRx Pharmaceuticals Funding Round
Streeterville Capital joined a $11 million capital raise for NRx Pharmaceuticals. The round was announced by the company on 11/7/2022.
Transaction Overview
Company Name
Announced On
11/7/2022
Transaction Type
Debt
Amount
$11,000,000
Round
Undisclosed
Investors
Streeterville Capital (Lead Investor)
Proceeds Purpose
The Company intends to use the net proceeds from the Note (approximately $10 million) to support its NRX-101 development programs for the treatment of suicidal bipolar depression and PTSD and for general corporate purposes.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1201 N Market St 111
Wilmington, DE 19801
USA
Wilmington, DE 19801
USA
Phone
Website
Email Address
Overview
We are NRx -- an agile and specialized biopharma company, resolutely focused on meeting very high unmet medical needs. We boldly address the life-threatening diseases facing the world today that often go untreated -- by researching, developing, and scaling solutions to help people who most desperately need them. We leverage proven science and clinical expertise to identify and apply medical solutions as immediately as possible, while simultaneously focusing on expanding therapeutic potential for the future.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Stephen Willard
Chief Financial Officer
Seth Voorhees
Co-Founder
Dennis McBride
Browse more venture capital transactions:
Prev: 11/7/2022: Exotanium venture capital transaction
Next: 11/7/2022: Kodehyve venture capital transaction
Share this article
Where The Data Comes From
We document all VC transactions involving tech companies. All VC database entries on this site come from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs